NCT00228059View on ClinicalTrials.gov

An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder.

PHASE3CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions
Bipolar I Disorder
Interventions
DRUG

Licarbazepine

Trial Locations (1)

Unknown

Investigational Site, Cerritos

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00228059 - An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder. | Biotech Hunter | Biotech Hunter